Pregnancy-induced atypical haemolytic uremic syndrome: A new era with eculizumab

Obstet Med. 2018 Mar;11(1):28-31. doi: 10.1177/1753495X17704563. Epub 2017 May 18.

Abstract

Pregnancy is a well-recognised trigger of atypical haemolytic syndrome (P-aHUS) and often occurs in the post-partum period. Similar to atypical haemolytic uremic syndrome, it carries a poor prognosis with high morbidity particularly in the form of renal failure. Early recognition and intervention is crucial in its management particularly with the recent availability of eculizumab, a humanized monoclonal antibody to complement component C5, which has demonstrated drastic improvement in prognosis. The issue, however, is arriving at a timely diagnosis given the considerable amount of overlap in the clinical and biochemical manifestation of P-aHUS, HELLP syndrome (haemolysis, elevated liver enzyme and low platelet count) and other hypertensive disorders of pregnancy. We present a case report and literature review that highlights the clinical conundrum of arriving at the diagnosis. We also highlight the importance of early management of P-aHUS with eculizumab and its impact on improving morbidity.

Keywords: Atypical haemolytic uremic syndrome; eculizumab; elevated liver enzymes; haemolysis; low platelet syndrome; preeclampsia; renal failure.

Publication types

  • Case Reports